Adjuvant chemotherapy with cisplatin and gemcitabine compared with standard of care after curative intent resection of cholangiocarcinoma and muscle-invasive gallbladder carcinoma (ACTICCA-1/AIO-HEP-0112 trial).
A Stein, J Bridgewater, H-J Klümpen, T Gruenberger, J Shannon, L Fornaro, L H Jensen, D Arnold, J Primrose, D Goldstein, A W Lohse, J Wilmink, U Pession, D P Modest, S Kasper, H S Wasan, D Palmer, J de Vos-Geelen, G Folprecht, A Möhl, A Pepić, E Vettorazzi, H Wege, ACTICCA-1 Investigators
Ann Oncol S0923-7534(26)08068-3
摘要
摘要
BACKGROUND: Despite curative resection and adjuvant capecitabine, ∼50% of patients with biliary tract cancer (BTC) have tumour recurrence or die within 2 years. This study evaluated the established palliative chemotherapy regimen with cisplatin and gemcitabine (CisGem) in the adjuvant setting. PATIENTS AND METHODS: ACTICCA-1 is a randomised, phase III investigator-initiated trial. Patients were enrolled at 67 sites across 8 countries between September 2017 and January 2023 and randomised to CisGem or capecitabine as adjuvant treatment regimen, each for a planned duration of 24 weeks. The primary endpoint is disease-free survival (DFS). Secondary endpoints include overall survival (OS), safety, and tolerability. RESULTS: In total, 591 patients have been randomly assigned. Median follow-up was 4.8 years. Median age was 63 years, 46.9% were women, and median interval between surgery and enrolment was 67 days. Primary tumour location was intrahepatic in 28.3%, perihilar in 19%, distal in 36.5%, and gallbladder in 16.2%; 47.9% of patients had lymph node-positive disease. CisGem showed a median DFS of 25.7 compared with 17.9 months for capecitabine (log rank P = 0.097). As predefined in the statistical analysis plan, due to violation of proportional hazard assumption, a Cox model was not feasible, and restricted mean survival time (RMST) was analysed. Patients receiving CisGem experienced on average 2.6 additional DFS months (95% confidence interval 0.6-4.68) compared with capecitabine (RMST in the first 3 years, P = 0.011), but no significant improvement in OS was observed (RMST P = 0.076; median 58.1 versus 48.2 months). Toxicity showed a higher number of severe adverse events (AEs; 130 versus 113 with 51 versus 47 assessed as treatment related) and a higher AE rate with CisGem (74.7%) compared with capecitabine (69.5%). CONCLUSION: CisGem did not statistically improve DFS compared with capecitabine and should thus not be applied as standard of care in the adjuvant setting.
KM 提取结果
0 个 Figure · 0 个 KM 面板